Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

SNDL Reports Third Quarter 2026 Financial and Operational Results

1 hour ago 8

PROTECT YOURSELF with Orgo-Life® QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Author of the article:

GlobeNewswire

Published Oct 27, 2026

24 minute read

Article content

The Company Makes Significant Strategic Investments While Improving Underlying Financial Performance and Generating Record Quarterly Free Cash Flow of $20 Million

Financial Post

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

  • Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
  • Daily content from Financial Times, the world's leading global business publication.
  • Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
  • National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
  • Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

  • Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
  • Daily content from Financial Times, the world's leading global business publication.
  • Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
  • National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
  • Daily puzzles, including the New York Times Crossword.

REGISTER / SIGN IN TO UNLOCK MORE ARTICLES

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account.
  • Share your thoughts and join the conversation in the comments.
  • Enjoy additional articles per month.
  • Get email updates from your favourite authors.

THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account
  • Share your thoughts and join the conversation in the comments
  • Enjoy additional articles per month
  • Get email updates from your favourite authors

Sign In or Create an Account

or

Article content

EDMONTON, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ/CSE: SNDL) (“SNDL” or the “Company”) reported its financial and operational results for the third quarter ended September 30, 2026. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

Article content

Article content

Advertisement 1

Article content

SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com.

Article content

By signing up you consent to receive the above newsletter from Postmedia Network Inc.

Article content

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026. The conference call details can be found below.

Article content

MANAGEMENT HIGHLIGHTS

Article content

  • Net revenue for the third quarter of 2026 was $238.0 million, representing a -2.5% decrease compared with the same period of the prior year. Cannabis Retail revenue increased by 0.7%, while Liquor Retail and Cannabis Operations revenue declined by -3.3% and -27.7%, respectively.
  • Gross profit of $57.9 million for the third quarter of 2026 represents a decline of $(6.3) million, or -9.8%, compared with the same period of the prior year.
  • Gross margin (1) was 24.3% in the third quarter of 2026, a decrease of 2.0 percentage points compared with the same period of the prior year, primarily reflecting weak performance of Cannabis Operations. Both retail segments delivered strong margin expansion and reached new quarterly records.
  • Operating loss was $(48.3) million for the third quarter of 2026, reflecting a $52 million non-cash goodwill impairment charge related to the Cannabis Operations segment.
  • Adj. operating income (1), which excludes impairment charges and restructuring costs, returned to positive territory at $5.2 million, an improvement of $14.8 million compared with the same period of the prior year.
  • Cash flow was $(50.7) million, reflecting $60.8 million of strategic investments in the U.S. and $10.0 million of additional share repurchases, consistent with our capital allocation priorities.
  • Free cash flow (1) reached a new quarterly record of $20.0 million in the third quarter of 2026, an increase of $3.3 million, or 19.5%, compared with the same period of the prior year, including a $10.6 million benefit associated with the initial unwinding of the Company’s captive insurance arrangement.

Article content

Advertisement 2

Article content

“Our third quarter results demonstrate improvement in SNDL’s underlying financial performance, including positive adjusted operating income and record quarterly free cash flow generation,” said Zach George, Chief Executive Officer of SNDL. “Cannabis Retail delivered record quarterly revenue and gross margin, Liquor Retail also reached a new record quarterly gross margin, and our Investments segment benefited from improved results from equity-accounted investees.”

Article content

“Cannabis Operations remained below expectations and recorded a non-cash impairment. While the quarter was impacted by inventory issues arising from the first half, we are taking decisive action to simplify the portfolio, reduce costs and concentrate resources on product categories where SNDL’s manufacturing capabilities, distribution reach and retail insights can support sustainable returns. The benefits of the actions taken during the quarter are expected to begin contributing to results in the fourth quarter. In addition to these immediate actions, the Company is initiating a strategic review of the Cannabis Operations segment to assess opportunities to improve its financial performance. The review will consider a range of strategic and operational alternatives, from potential asset divestitures to larger productivity initiatives.”

Advertisement 1

Advertisement 2

Article content

“The completion of the restructuring of Surterra Holdings, Inc. (“Parallel”) in July of this year, which reduced its debt burden by approximately US$842 million, and the subsequent rights offering, which increased our indirect equity ownership from approximately 67% to 92%, represent important steps in resetting Parallel’s capital structure and providing liquidity to support inventory, product availability and critical supply-chain infrastructure. SNDL-funded investments by SunStream Bancorp Inc. (“SunStream”) in a new cultivation facility in Gainesville, Florida, are expected to enhance Parallel’s cost structure. We are excited by the opportunity presented by our investment in Parallel and are actively exploring the feasibility of transitioning our indirect economic exposure to direct ownership and consolidation of qualifying U.S. medical cannabis operations, subject to applicable legal, regulatory, accounting and Nasdaq requirements.”

Article content

“We are encouraged by the progress made toward resolving the regulatory matters involving the Alcohol and Gaming Commission of Ontario (“AGCO”), which we expect will provide greater clarity for the Ontario franchise retail operations and future development opportunities, as further detailed later in this document and in the Q3 2026 Earnings Call presentation.”

Article content

Advertisement 3

Article content

“Across SNDL, our priorities remain disciplined capital allocation, improved operating performance and long-term value creation for shareholders. We have demonstrated that commitment through significant share repurchases, and we intend to remain aggressive when we believe the opportunity to acquire our shares represents an attractive use of capital. The recently announced potential $50 million substantial issuer bid (“SIB”) is a further step toward accelerating capital returns and reducing our outstanding share count,” concluded Zach George.

Article content

TOTAL COMPANY HIGHLIGHTS

Article content

 Three months ended September 30 Nine months ended September 30 
($000s)2026 2025 % Change 2026 2025 % Change 
IFRS Financial Measures            
Net revenue 237,994  244,219  -2.5% 669,666  693,902  -3.5%
Gross profit 57,886  64,177  -9.8% 167,047  188,419  -11.3%
Operating income (loss) (48,317) (11,050) -337.3% (65,272) (18,100) -260.6%
Change in cash and cash equivalents (50,729) 32,357  -256.8% (107,622) 22,222  -584.3%
             
Non-IFRS Financial Measures
(1)
            
Gross margin 24.3% 26.3% -2.0pp 24.9% 27.2% -2.2pp
Adjusted operating income (loss) 5,249  (9,512) 155.2% (10,675) (12,713) 16.0%
Free cash flow 19,954  16,692  19.5% 5,692  7,733  -26.4%
 

Article content

Advertisement 4

Article content

(1)   Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have standardized meanings under IFRS and therefore may not be comparable to similar measures reported by other companies. See “Non-IFRS Measures” section below for further information.

Article content

BUSINESS SEGMENT HIGHLIGHTS

Article content

SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company’s licensed retail subsidiaries for resale. Corporate and shared service expenses are reported as “Corporate”.

Article content

 Three months ended September 30 Nine months ended September 30 
($000s)2026 2025(2) % Change 2026 2025(2) % Change 
Net Revenue            
Cannabis Retail 85,605  85,021  0.7% 246,154  246,960  -0.3%
Cannabis Operations 27,040  37,389  -27.7% 88,704  107,544  -17.5%
Intersegment Eliminations (9,425) (17,579) 46.4% (38,757) (51,391) 24.6%
Total Cannabis 103,220  104,831  -1.5% 296,101  303,113  -2.3%
Liquor Retail 134,774  139,388  -3.3% 373,565  390,789  -4.4%
Investments —  —  0.0% —  —  0.0%
Total 237,994  244,219  -2.5% 669,666  693,902  -3.5%
             
Operating Income            
Cannabis Retail 5,244  5,047  3.9% 9,328  10,557  -11.6%
Cannabis Operations (64,693) (10,882) -494.5% (80,836) (20,186) -300.5%
Total Cannabis (59,449) (5,835) -918.8% (71,508) (9,629) -642.6%
Liquor Retail 6,035  6,591  -8.4% 5,899  10,884  -45.8%
Investments 7,861  1,543  409.5% 8,340  1,775  369.9%
Corporate (2,764) (13,349) 79.3% (8,003) (21,130) 62.1%
Total (48,317) (11,050) -337.3% (65,272) (18,100) -260.6%
             
Adjusted Operating Income            
Cannabis Retail 5,284  5,047  4.7% 9,403  10,557  -10.9%
Cannabis Operations (11,391) (10,220) -11.5% (27,303) (16,258) -67.9%
Total Cannabis (6,107) (5,173) -18.1% (17,900) (5,701) -214.0%
Liquor Retail 6,037  6,591  -8.4% 6,126  10,884  -43.7%
Investments 7,861  1,543  409.5% 8,340  1,775  369.9%
Corporate (2,542) (12,473) 79.6% (7,241) (19,671) 63.2%
Total 5,249  (9,512) 155.2% (10,675) (12,713) 16.0%
 

Advertisement 2

Advertisement 3

Article content

(2)   In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period, as documented in the condensed interim Financial Statements.

Article content

Liquor Retail 

Article content

SNDL is Canada’s largest private-sector liquor retailer, operating as of October 26, 2026 in 165 locations, predominantly in Alberta, under its three retail banners: “Wine and Beyond” (16), “Liquor Depot” (19), and “Ace Liquor” (130).

Article content

 Three months ended September 30 Nine months ended September 30 
($000s)2026 2025 % Change 2026 2025 % Change 
Net revenue 134,774  139,388  -3.3% 373,565  390,789  -4.4%
Gross profit 36,390  36,704  -0.9% 96,828  100,993  -4.1%
Gross margin 27.0% 26.3% 0.7pp 25.9% 25.8% 0.1pp
Operating income 6,035  6,591  -8.4% 5,899  10,884  -45.8%
Adjusted operating income 6,037  6,591  -8.4% 6,126  10,884  -43.7%
                   

Article content

  • Net revenue for Liquor Retail continued to decline year over year in the third quarter of 2026, although at a slightly better rate than in previous quarters. Persistent softness in market demand continued to affect same-store sales(3), which decreased by -6.0% compared with the same period in the prior year.
  • Operating income declined year over year, driven by lower revenue, increased promotional support, and higher SG&A expenses associated with the recent Wine & Beyond store openings, partly offset by strong gross margin expansion, which reached a new quarterly record.

Article content

Advertisement 5

Article content

(3)   Same-store sales is a specified financial measure that does not have standardized meanings under IFRS and therefore may not be comparable to similar measures used by other companies. See “Non-IFRS Measures” section below for further information.

Article content

Cannabis Retail

Article content

SNDL is one of Canada’s largest private-sector cannabis retailers, operating as of October 26, 2026 in 193 locations under two retail banners: “Value Buds” (133) and “Spiritleaf” (60, of which 4 are corporate stores and 56 are franchise stores). The Company’s Cannabis Retail strategy is based on several pillars, including high-quality store locations, a broad product assortment and differentiated customer experiences. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

Article content

 Three months ended September 30 Nine months ended September 30 
($000s)2026 2025 % Change 2026 2025 % Change 
Net revenue 85,605  85,021  0.7% 246,154  246,960  -0.3%
Gross profit 23,118  22,465  2.9% 65,472  63,974  2.3%
Gross margin 27.0% 26.4% 0.6pp 26.6% 25.9% 0.7pp
Operating income 5,244  5,047  3.9% 9,328  10,557  -11.6%
Adjusted operating income 5,284  5,047  4.7% 9,403  10,557  -10.9%
                   

Article content

Advertisement 6

Article content

  • Net revenue for Cannabis Retail returned to growth in the third quarter compared with the same period of the prior year, consistent with the previously anticipated inflection point, and reached a new quarterly record. Market contraction in our largest provinces (ON, AB) contributed to a -3.8% decline in same-store sales. This decline was partially offset by incremental revenue from new stores and Value Buds store conversions.
  • Operating income increased compared with the same period of the prior year, primarily driven by gross margin expansion, which reached a new quarterly record, despite lapping a larger impairment reversal recorded in the third quarter of 2025.
  • Subject to completion of definitive documentation and payment of a $200,000 monetary penalty, the anticipated resolution of the regulatory matters involving the AGCO is expected to allow the Value Buds franchise network to resume growth in Ontario following a pause of more than a year during the regulatory review. While the contemplated structure is expected to result in the deconsolidation of the Ontario retail operations from SNDL’s financial statements, we expect the overall commercial arrangements to substantially preserve SNDL’s net economics associated with these franchise locations, without retaining control over the retail operations in the province.

Advertisement 3

Advertisement 4

Article content

Cannabis Operations

Article content

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL’s vertical integration strategy.

Article content

 Three months ended September 30 Nine months ended September 30 
($000s)2026 2025 % Change 2026 2025 % Change 
Net revenue 27,040  37,389  -27.7% 88,704  107,544  -17.5%
Gross profit (1,622) 5,008  -132.4% 4,747  23,452  -79.8%
Gross margin -6.0% 13.4% -19.4pp 5.4% 21.8% -16.5pp
Operating income (loss) (64,693) (10,882) -494.5% (80,836) (20,186) -300.5%
Adjusted operating income (loss) (11,391) (10,220) -11.5% (27,303) (16,258) -67.9%
                   

Article content

  • Our Cannabis Operations results remain below our expectations, and we are moving aggressively to reshape the segment into a more focused and efficient business. Most of the revenue decline in the third quarter was attributable to our exit from the unprofitable domestic dried flower category and our increased focus on higher-value products.
  • Profitability was impacted by a $52 million non-cash goodwill impairment reflecting current business trends, as well as $6 million in other impacts, mostly driven by inventory adjustments related to the exit from the dried flower category and Jeeter cost variances. During the third quarter, we took decisive actions to reduce manufacturing costs and other operating expenses, particularly at our Kelowna manufacturing facility, including a reduction of more than 30% of the workforce at the site. The P&L benefits of these cost reductions are expected to begin contributing to results in the fourth quarter.

Article content

Advertisement 7

Article content

Investments

Article content

  • As of September 30, 2026, the Company’s portfolio of cannabis-related investments had a carrying value of $485.2 million, including $467.7 million to SunStream Bancorp Inc. (“SunStream”). This carrying value was increased by $70.0 million during the third quarter of 2026, primarily driven by additional contributions to fund the buildout of the Gainesville, Florida cultivation facility, SNDL’s participation in Parallel’s rights offering, and the purchase of an incremental portion of Parallel’s debt.
  • On July 27, 2026, the restructuring of Parallel was completed, providing SNDL with indirect majority economic exposure to the company. During the third quarter, SNDL participated in a Parallel rights offering, while other minority holders declined to participate, increasing SNDL’s indirect equity interest from approximately 67% to approximately 92%. SNDL continues to evaluate a pathway to directly own and consolidate Parallel’s U.S. medical cannabis operations while maintaining compliance with the applicable Nasdaq requirements. Consistent with recent public-market precedents, SNDL is evaluating structures that distinguish medical cannabis operations from adult-use exposure, with the latter expected to remain outside SNDL’s consolidated operations. The Company is actively advancing this work and expects to provide further clarity as the structure and timing are finalized, subject to applicable legal, regulatory, accounting and Nasdaq requirements.
  • Following the completion of Parallel’s restructuring, SNDL also financed SunStream’s purchase of an additional portion of Parallel’s takeback debt at 75% of face value, increasing SunStream’s debt ownership from 39.4% to 69.4%.
  • The Investments segment generated $7.9 million of operating income during the third quarter of 2026, including $6.9 million from SNDL’s share of profit from SunStream’s equity-accounted investees, primarily reflecting an increase in the valuation of Parallel.
  • The previously disclosed restructuring process relating to Skymint continues. On April 1, 2026, the Michigan Supreme Court agreed to hear oral argument on applications for leave to appeal. The Court has not reached a decision on the merits. Timing and outcomes remain uncertain and are subject to court process and other factors.
  • On April 23, 2026, the United States Department of Justice and the United States Drug Enforcement Administration issued an order placing Food and Drug Administration-approved cannabis products and qualifying state-regulated medical cannabis in Schedule III of the United States Controlled Substances Act, while initiating an expedited administrative process to consider the broader rescheduling of cannabis, including adult-use cannabis, from Schedule I to Schedule III. The administrative hearing concluded in July 2026, with a final determination on broader rescheduling still pending.

Article content

Advertisement 8

Article content

Equity Position

Article content

  • $617.8 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at September 30, 2026, resulting in a net book value of $1.0 billion.
  • During the third quarter of 2026, the Company purchased for cancellation 5,431,300 common shares at a weighted average price, excluding commissions, of US$1.31 per share. Year-to-date through October 22, 2026, the Company had purchased for cancellation 23,088,153 common shares, resulting in 243,320,644 common shares outstanding.
  • As recently communicated, the Company’s Board of Directors has directed management to pursue a possible substantial issuer bid (“SIB”) for an aggregate purchase price of up to C$50 million and at a price per share not exceeding C$1.92 (US$1.35). If completed and fully subscribed at the maximum price, the SIB could reduce the Company’s common shares outstanding by more than an additional 10%. SNDL will continue to evaluate opportunities to repurchase shares where management believes doing so is in the best interests of SNDL and its shareholders. In this context, and subject to approval by SNDL’s Board of Directors, we expect to proceed with the renewal of the share repurchase program upon its expiration on November 20, 2026, supported by continued free cash flow and potential targeted asset sales, including non-core real estate and other operating assets.

Advertisement 4

Advertisement 5

Article content

This press release is intended to be read in conjunction with the Company’s condensed consolidated interim financial statements and the notes thereto for the three and nine months ended September 30, 2026, and the accompanying Management’s Discussion and Analysis. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml. 

Article content

CONFERENCE
CALL  

Article content

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026.

Article content

WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/wcotys5n

Article content

REPLAY

Article content

Article content

ABOUT SNDL INC. 

Article content

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.comFor more information: 
Tomas Bottger
Investor Relations, SNDL Inc. 
O: 1.587.327.2017 
E: [email protected]

Article content

Advertisement 9

Article content

Forward-Looking Information Cautionary Statement    
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”), including, but not limited to, statements regarding the Company’s operational goals, plans and key priorities, the strategic review of the Cannabis Operations segment, including its scope, potential alternatives and outcomes, and the expected benefits of any actions resulting from the review, the Company’s ability to deploy capital and the expected benefits thereof, expectations related to the Jeeter contract, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, the feasibility, structure, timing and expectations related to the Company obtaining direct ownership and control of, and consolidating, qualifying U.S. medical cannabis operations of Parallel, SNDL’s corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the enterprise resource planning (“ERP”) system consolidation, SNDL’s ability to recover the senior secured notes held in Cannabist, the timing and expected impact of reclassifying cannabis from Schedule I to Schedule III under the United States Controlled Substances Act, the Company’s retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see “Risk Factors” in the Company’s annual information form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. 

Article content

Advertisement 10

Article content

Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Expressed in thousands of Canadian dollars, except per share amounts)
 
  Three months ended
September 30
  Nine months ended
September 30
 
  2026  2025  2026  2025 
Net revenue  237,994   244,219   669,666   693,902 
Cost of sales  180,108   180,042   502,619   505,483 
Gross profit  57,886   64,177   167,047   188,419 
             
Investment income  927   1,777   3,472   6,162 
Share of profit (loss) of equity-accounted investees  6,934   (234)  5,084   (4,387)
             
General and administrative  43,284   45,967   132,732   137,702 
Sales and marketing  3,462   3,617   11,136   10,768 
Depreciation and amortization  12,659   12,928   38,145   39,076 
Share-based compensation  1,767   10,883   5,033   15,190 
Restructuring costs  577   1,134   1,608   2,287 
Asset impairment, net  52,331   2,051   52,151   2,971 
Other income  —   —   (81)  — 
Research and development  —   156   12   354 
(Gain) loss on disposition of assets  (16)  34   139   (54)
Operating loss  (48,317)  (11,050)  (65,272)  (18,100)
             
Other expenses, net  (2,464)  (2,269)  (6,424)  (7,041)
Loss before income tax  (50,781)  (13,319)  (71,696)  (25,141)
Income tax (expense) recovery  (8)  —   3,174   — 
Net loss  (50,789)  (13,319)  (68,522)  (25,141)
             
Equity-accounted investees – share of other comprehensive (loss) income  (29)  7,709   10,625   (13,250)
Investments at fair value through other comprehensive income (“FVOCI”) – change in fair value  2,773   12,940   1,690   9,754 
Comprehensive (loss) income  (48,045)  7,330   (56,207)  (28,637)
             

Advertisement 5

Advertisement 6

Article content

Condensed Consolidated Interim Statement of Financial Position
(Expressed in thousands of Canadian dollars)
 
As atSeptember 30, 2026 December 31, 2025 
     
Assets    
Current assets    
Cash and cash equivalents 132,479  252,243 
Restricted cash 8,162  20,081 
Marketable securities 139  84 
Accounts receivable 31,734  27,643 
Biological assets 2,407  3,120 
Inventory 128,721  126,877 
Prepaid expenses and deposits 16,614  15,566 
Investments 106  484 
Assets held for sale 700  746 
Net investment in subleases 2,997  2,775 
  324,059  449,619 
Non-current assets    
Long-term deposits and receivables 2,457  4,526 
Right of use assets 131,608  138,353 
Property, plant and equipment 139,376  151,900 
Net investment in subleases 9,954  11,643 
Intangible assets 56,434  58,520 
Investments 17,314  11,574 
Equity-accounted investees 467,730  385,534 
Goodwill 75,238  124,248 
Total assets 1,224,170  1,335,917 
     
Liabilities    
Current liabilities    
Accounts payable and accrued liabilities 46,902  56,747 
Lease liabilities 35,706  35,462 
  82,608  92,209 
Non-current liabilities    
Lease liabilities 126,614  134,471 
Other liabilities 7,753  8,041 
Total liabilities 216,975  234,721 
     
Shareholders’ equity    
Share capital 2,127,355  2,310,398 
Warrants 306  306 
Contributed surplus 53,377  54,038 
Accumulated deficit (1,225,053) (1,302,441)
Accumulated other comprehensive income (“AOCI”) 51,210  38,895 
Total shareholders’ equity 1,007,195  1,101,196 
Total liabilities and shareholders’ equity 1,224,170  1,335,917 
       

Article content

Advertisement 11

Article content

Condensed Consolidated Interim Statement of Cash Flows
(Expressed in thousands of Canadian dollars)
 
  Three months ended
September 30
  Nine months ended
September 30
 
  2026  2025  2026  2025 
Cash provided by (used in):            
Operating activities            
Net loss for the period  (50,789)  (13,319)  (68,522)  (25,141)
Adjustments for:            
Income tax expense (recovery)  8   —   (3,174)  — 
Interest and fee income  (927)  (1,675)  (3,417)  (5,849)
Change in fair value of biological assets  585   180   594   (2,559)
Change in fair value of inventory sold  (276)  349   249   1,313 
Share-based compensation  1,767   10,883   5,033   15,190 
Depreciation and amortization  13,893   13,972   41,998   42,108 
(Gain) loss on disposition of assets  (16)  34   139   (54)
Inventory impairment and obsolescence  3,455   1,833   6,057   2,663 
Finance costs, net  1,951   1,812   6,007   5,149 
Change in estimate of fair value of derivative warrants  —   (1)  —   (26)
Unrealized foreign exchange loss (gain)  180   (153)  (832)  40 
Transaction costs  —   —   10   — 
Asset impairment, net  52,331   2,051   52,151   2,971 
Share of (profit) loss of equity-accounted investees  (6,934)  234   (5,084)  4,387 
Unrealized (gain) on marketable securities  —   (102)  (55)  (313)
Additions to marketable securities  —   —   151   313 
Income distributions from equity-accounted investees  315   —   315   68 
Interest received  822   1,409   3,377   5,628 
Exercise of cash-settled deferred share units  —   —   (474)  — 
Change in non-cash working capital  2,185   14,194   (8,805)  (282)
Net cash provided by operating activities  18,550   31,701   25,718   45,606 
Investing activities            
Additions to property, plant and equipment  (1,196)  (5,185)  (5,620)  (8,853)
Additions to investments  —   —   (4,183)  (16,414)
Principal payments from investments  121   129   359   27,293 
Proceeds from disposal of investments  —   15,058   —   15,058 
Capital (contributions) distributions from equity-accounted investees  (60,762)  481   (63,628)  4,273 
Proceeds from disposal of property, plant and equipment  538   —   2,332   166 
Acquisitions  —   —   (2,900)  (1,000)
Change in non-cash working capital  75   39   712   10 
Net cash (used in) provided by investing activities  (61,224)  10,522   (72,928)  20,533 
Financing activities            
Change in restricted cash  11,950   —   11,950   — 
Payments on lease liabilities, net  (10,228)  (9,920)  (30,385)  (29,217)
Repurchase of common shares  (10,042)  (3)  (43,113)  (15,034)
Change in non-cash working capital  265   57   1,136   334 
Net cash used in financing activities  (8,055)  (9,866)  (60,412)  (43,917)
Change in cash and cash equivalents  (50,729)  32,357   (107,622)  22,222 
Adjustment on initial application of amendments to IFRS 9 on January 1, 2026  —   —   (12,142)  — 
Cash and cash equivalents, beginning of period  183,208   208,224   252,243   218,359 
Cash and cash equivalents, end of period  132,479   240,581   132,479   240,581 
                 

Article content

Advertisement 12

Article content

NON-IFRS MEASURES

Article content

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company’s operating results in the same manner as the management team.  

Article content

ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

Article content

The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.

Advertisement 6

Advertisement 7

Article content

($000s)Cannabis
Retail
 Cannabis
Operations
 Cannabis
Total
 Liquor
Retail
 Investments Corporate Total 
Three months ended September 30, 2026 
Operating income (loss) 5,244  (64,693) (59,449) 6,035  7,861  (2,764) (48,317)
Adjustments:              
Restructuring costs 40  313  353  2  —  222  577 
Goodwill and intangible asset impairments —  52,022  52,022  —  —  —  52,022 
Impairments triggered by restructuring —  967  967  —  —  —  967 
Adjusted operating income (loss) 5,284  (11,391) (6,107) 6,037  7,861  (2,542) 5,249 

Article content

($000s)Cannabis
Retail
 Cannabis
Operations
 Cannabis
Total
 Liquor
Retail
 Investments Corporate Total 
Nine months ended September 30, 2026 
Operating income (loss) 9,328  (80,836) (71,508) 5,899  8,340  (8,003) (65,272)
Adjustments:              
Restructuring costs 75  544  619  227  —  762  1,608 
Goodwill and intangible asset impairments —  52,022  52,022  —  —  —  52,022 
Impairments triggered by restructuring —  967  967  —  —  —  967 
Adjusted operating income (loss) 9,403  (27,303) (17,900) 6,126  8,340  (7,241) (10,675)

Article content

($000s)Cannabis
Retail
 Cannabis
Operations
 Cannabis
Total
 Liquor
Retail
 Investments Corporate Total 
Three months ended September 30, 2025 
Operating income (loss)(1) 5,047  (10,882) (5,835) 6,591  1,543  (13,349) (11,050)
Adjustments:              
Restructuring costs —  258  258  —  —  876  1,134 
Impairments triggered by restructuring —  404  404  —  —  —  404 
Adjusted operating income (loss) 5,047  (10,220) (5,173) 6,591  1,543  (12,473) (9,512)
($000s)Cannabis
Retail
 Cannabis
Operations
 Cannabis
Total
 Liquor
Retail
 Investments Corporate Total 
Nine months ended September 30, 2025 
Operating income (loss)(1) 10,557  (20,186) (9,629) 10,884  1,775  (21,130) (18,100)
Adjustments:              
Restructuring costs —  828  828  —  —  1,459  2,287 
Impairments triggered by restructuring —  3,100  3,100  —  —  —  3,100 
Adjusted operating income (loss) 10,557  (16,258) (5,701) 10,884  1,775  (19,671) (12,713)
                      

Article content

Advertisement 13

Article content

(4)   In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

Article content

GROSS MARGIN
Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company’s ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments

Article content

FREE CASH FLOW

Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company’s ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

Article content

Advertisement 14

Article content

The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

Article content

  Three months ended
September 30
  Nine months ended
September 30
 
($000s) 2026  2025  2026  2025 
Change in cash and cash equivalents  (50,729)  32,357   (107,622)  22,222 
Adjustments:            
Repurchase of common shares  10,042   3   43,113   15,034 
Changes to long-term investments  60,641   (15,668)  67,301   (30,523)
Acquisitions, net of cash acquired  —   —   2,900   1,000 
Free cash flow  19,954   16,692   5,692   7,733 
                 

Article content

SAME-STORE SALES
Same-store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company’s sales trends excluding the effect of the opening and closure of stores.

Article content

Same store sales refers to the revenue generated by the Company’s existing retail locations during the current and prior comparison periods.

Article content

ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including ERP implementation costs and litigation settlements, net of recoveries.

Advertisement 7

Advertisement 8

Article content

  Three months ended
September 30
  Nine months ended
September 30
 
($000s) 2026  2025  2026  2025 
Net earnings (loss)  (50,789)  (13,319)  (68,522)  (25,141)
Adjustments:            
Inventory and biological assets fair value and impairment adjustments  3,764   2,362   6,900   1,417 
Share of loss (profit) of equity-accounted investees  (6,934)  234   (5,084)  4,387 
Depreciation and amortization  12,659   12,928   38,145   39,076 
Share-based compensation  1,767   10,883   5,033   15,190 
Restructuring costs  577   1,134   1,608   2,287 
Asset (reversal) impairment  52,331   2,051   52,151   2,971 
Loss (gain) on disposition of PP&E  (16)  34   139   (54)
Other expenses, net  2,464   2,269   6,424   7,041 
Income tax recovery  8   —   (3,174)  — 
Non-recurring items  (15)  (501)  549   (696)
Adjusted EBITDA  15,816   18,075   34,169   46,478 
                 

Article content

Article content

Article content

Article content

Article content

Article content

Article content

Advertisement 8

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway